Week In Review: Vivace Details Its Capital Efficient Plan To Develop Novel Cancer Therapies

Published: Jul 31, 2017

Company Spotlight
- In an exclusive interview, Sofie Qiao, PhD, President/CEO of Vivace Therapeutics, discussed the novel science behind Vivace's portfolio and the company's US-China capital-efficient business plan;
Deals and Financings
- Seattle's Rodeo Therapeutics announced a $5.9 million financing, including participation by WuXi AppTec, for small-molecule therapies to promote tissue repair;
- Nanjing Frontier Biotechnologies acquired global rights to a novel broad-spectrum HIV neutralizing antibody from Rockefeller University of the US;
Industry Insights
- We list and profile the top 10 China pharma companies ranked by a combination of each company's revenues and market capitalization;
Trials and Approvals
- The CFDA approved a superficial radiation therapy device made by Sensus Healthcare of the US to treat and prevent keloids;
- DelMar Pharma, a Canada-US biopharma, was approved to start a China Phase II trial of its lead candidate, which targets glioblastoma multiforme.

Back to news